Ensuring Regulatory Transparency as Mandated by GDUFA

The U.S. Food and Drug Administration (FDA) annually publishes the Activities Report of the Generic Drug Program, as required by Sections 805 and 807 of the Food and Drug Administration Reauthorization Act of 2017 (FDARA). This report aims to maximize transparency in the regulatory review process for Abbreviated New Drug Applications (ANDAs), enabling generic manufacturers to establish predictable market entry strategies. In Fiscal Year 2024 (FY 2024), the FDA's Office of Generic Drugs (OGD) processed 1,217 final approvals and 483 tentative approvals, contributing to the stabilization of the drug supply chain. These regular reports play a crucial role in improving the efficiency of the U.S. generic drug market, valued at approximately USD 130 billion, by proactively quantifying regulatory delay factors.

Impact of CGT Designation and 180-Day Market Exclusivity

A key indicator in this report is the status and approval data for Competitive Generic Therapy (CGT) designated drugs. The CGT program was introduced to encourage the development of generics for drugs with one or fewer competitors in the U.S. market, offering expedited development and a 180-day market exclusivity. This provides significant regulatory incentives for major companies like Teva Pharmaceutical Industries (TEVA) and Viatris (VTRS) to secure first-generic status and generate substantial early profits. The reduction in CGT ANDA review times directly impacts the speed at which alternative drugs become available after the expiration of innovator drug patents, accelerating the reduction of healthcare costs for patients.

Delays in 180-Day Reviews of Suitability Petitions and Bottlenecks

The status of Suitability Petitions, disclosed in accordance with Section 805, has been identified as a significant bottleneck in the regulatory approval process. Suitability Petitions are preliminary requests that allow the submission of a generic ANDA when the generic drug differs from the original drug in terms of route of administration, formulation, or dosage. According to the FY 2025 report, of the 117 pending petitions, 67 have been delayed for more than 180 days. These delays can postpone the research and development (R&D) timelines for smaller biosimilar companies seeking to develop improved generics, leading to capital inefficiencies. Therefore, the prompt implementation of the Goal Dates system under GDUFA III is essential.

Pipeline Response Strategies for Global Generic Companies

The increased transparency in regulatory timelines is contributing to the portfolio diversification of major global generic pharmaceutical companies, including Sandoz Group AG (SDZNY). By concentrating resources on complex generics or pipelines targeting CGT designations, these companies can defend against margin erosion. Furthermore, the investment community can now observe the FDA's quarterly ANDA processing speed and changes in the number of pending Suitability Petitions, allowing for a more refined assessment of regulatory risk premiums in the generic drug industry. Ultimately, enhancing policy transparency to reduce regulatory uncertainty promotes capital inflows into the generic drug sector and fosters healthy market competition, thereby strengthening the sustainability of the healthcare system.